Alzheimer's Disease Diagnostics Market: as blood-based biomarker tests clear the same regulatory bar that used to require a PET scanner or a lumbar puncture, every primary care visit that can now rule out amyloid pathology converts a referral bottleneck into a same-day answer, so the diagnostic pathway is shifting from specialist imaging centres to community laboratories, and competitive advantage is moving toward platforms that can run on existing blood-draw infrastructure rather than those that require dedicated imaging capital.

The global Alzheimer's disease diagnostics market size was USD 9.94 Billion in 2025 and is expected to register a revenue CAGR of 10.9% during the forecast period. Market revenue growth is driven by factors such as the rising global prevalence of Alzheimer's disease in the aging population, the commercialisation of blood-based biomarker tests that no longer require imaging or lumbar puncture, and anti-amyloid therapy eligibility testing requirements. The first driving factor is the scale of Alzheimer's disease in the aging population. The Alzheimer's Association reported that over 7 million Americans were living with Alzheimer's in 2025, with approximately 6.9 million aged 65 and older, a figure projected to grow to 13.8 million by 2060. The second driving factor is the commercialisation of blood-based biomarker tests that clear the regulatory bar previously reserved for imaging and CSF analysis. Imaging techniques accounted for the largest revenue share in 2025 at approximately 40 to 45% of market revenue, but blood-based biomarker tests are now cleared for the same diagnostic purpose at a fraction of the cost and infrastructure requirement. The third driving factor is anti-amyloid therapy eligibility testing, since FDA-approved anti-amyloid monoclonal antibody treatments require confirmatory amyloid biomarker testing before prescribing. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single validated blood biomarker platform accumulates additional cleared use cases on the same installed laboratory instrument base, which converts one regulatory clearance into a widening set of billable testing scenarios without a new capital equipment purchase. Once a laboratory network adopts a cleared plasma biomarker assay, each additional cleared claim, such as a primary-care rule-out indication or a new biomarker ratio, adds billable testing volume to the same automated immunoassay platform already installed, so testing revenue per instrument compounds as the platform's cleared claim set widens around the same hardware. As a result, demand and revenue share are concentrating around platforms that hold the broadest set of cleared blood-biomarker claims, and the forecast tilts toward laboratories running FDA-cleared plasma assays rather than sending samples out for PET or CSF confirmation. For instance, in October 2025, Roche received FDA clearance for its Elecsys pTau181 test as the first blood-based biomarker assay indicated for use in the primary care setting specifically to rule out amyloid pathology, one of a widening set of blood-based Alzheimer's claims now running on Roche's existing installed automated immunoassay base. These are some of the key factors driving revenue growth of the market.

Because amyloid PET scans cost approximately USD 3,000 to USD 5,000 per procedure in the United States and require specialised radiopharmaceutical production infrastructure, access has been confined to major academic medical centres and specialist imaging facilities, which limits scalable identification of amyloid-positive patients in community healthcare settings.

Reimbursement history is a second constraint, because CMS Medicare coverage for amyloid PET was restricted through 2024 to one scan per lifetime under a Coverage with Evidence Development framework, creating an access barrier for elderly beneficiaries that blood-based testing has only recently begun to bypass.

Clinical interpretation infrastructure is a third constraint, since primary care physicians newly able to order a blood-based biomarker test still need clear referral pathways to specialist confirmation and treatment, so testing volume growth outpaces the memory-care specialist capacity needed to act on positive results.

These factors substantially limit Alzheimer's disease diagnostics market growth over the forecast period.

The clearest driver of demand is the arrival of FDA-cleared blood-based biomarker tests that can rule out amyloid pathology without imaging or lumbar puncture. A blood-based biomarker test works only if its plasma protein measurement correlates reliably enough with confirmed amyloid PET or CSF results to support a clinical decision, and once that correlation clears FDA review, the same automated immunoassay instruments already installed at reference laboratories nationwide can run the test at a fraction of the cost of PET. The Alzheimer's Association reported that over 7 million Americans were living with Alzheimer's in 2025, and Fujirebio's Lumipulse G pTau217/beta-amyloid 1-42 plasma ratio assay became the first blood-based test cleared to aid Alzheimer's diagnosis, with Labcorp launching it nationally in August 2025. In October 2025, Roche received FDA clearance for its Elecsys pTau181 test as the first blood-based biomarker assay indicated for the primary care setting, and Labcorp announced it would offer the test nationwide by early 2026. The effect on the market is that diagnostic testing volume can now scale through primary care blood draws rather than being capped by imaging centre and lumbar puncture capacity. These are some of the key factors driving revenue growth of the market.

The second driver is the regulatory requirement that anti-amyloid monoclonal antibody treatments be prescribed only after biomarker-confirmed amyloid pathology. Anti-amyloid therapy works by clearing amyloid plaques, so prescribing it to a patient without confirmed amyloid pathology exposes that patient to treatment risk without the corresponding clinical benefit, which is why FDA-approved anti-amyloid treatments carry a biomarker confirmation requirement built directly into their prescribing information. Lecanemab and donanemab, approved as anti-amyloid monoclonal antibody treatments in January 2023 and July 2024 respectively, both require confirmatory amyloid PET or CSF biomarker testing for patient eligibility verification before treatment can begin. In August 2025, C2N Diagnostics introduced its PrecivityAD2 blood test, positioned to compare favourably against existing PET and CSF confirmation options for the same eligibility-testing purpose. The effect on the market is that every prescription of an anti-amyloid therapy carries a corresponding diagnostic testing event, tying diagnostic volume growth directly to therapeutic uptake. These are some of the key factors driving revenue growth of the market.

Roche's Elecsys pTau181 test, cleared in October 2025, is the first blood-based Alzheimer's biomarker test indicated specifically for the primary care setting. Diagnosis is moving to wherever the blood draw already happens.

The third driver is the parallel international expansion of blood-based Alzheimer's testing clearance and deployment outside the United States. A blood biomarker test validated and cleared in one major regulatory jurisdiction still needs a separate national regulatory approval and local laboratory deployment before it can scale in another country, so international rollout depends on manufacturers and local laboratory partners pursuing that approval and deployment work market by market. China's National Medical Products Administration approved a five-biomarker Alzheimer's blood test in April 2024, and in January 2026 BGI Genomics and Roche Diagnostics deployed Alzheimer's disease blood tests in several Chinese cities following that approval. The effect on the market is that blood-based testing volume growth is no longer confined to the United States regulatory and reimbursement environment. These are some of the key factors driving revenue growth of the market.

However, the Alzheimer's disease diagnostics market faces severe adoption constraints from the high cost of confirmatory imaging and historically restrictive reimbursement for amyloid PET.

Because amyloid PET scans cost approximately USD 3,000 to USD 5,000 per procedure in the United States and require specialised radiopharmaceutical production and administration infrastructure, access has been confined to major academic medical centres and specialist PET imaging facilities, which limits the scalable identification of amyloid-positive patients eligible for anti-amyloid therapy in community healthcare settings even as blood testing expands the funnel feeding into it.

Reimbursement history compounds this, because CMS Medicare coverage for amyloid PET was restricted through 2024 to one scan per lifetime under a Coverage with Evidence Development framework tied to ClinicalTrials.gov data collection requirements, an access barrier that blood-based testing has only recently begun to bypass rather than fully resolve.

Specialist interpretation capacity is the third constraint, since a positive blood biomarker result from a primary care visit still requires referral to a memory clinic or neurologist for treatment decisions, so testing volume growth outpaces the specialist capacity needed to convert a positive screen into a confirmed diagnosis and treatment plan.

These factors substantially limit Alzheimer's disease diagnostics market growth over the forecast period.

Based on diagnostic technique, the global Alzheimer's disease diagnostics market is segmented into imaging techniques, biomarkers, cognitive assessment tests, and genetic testing. Imaging techniques hold the largest revenue share, because amyloid PET remains the definitive confirmatory standard against which blood-based tests are validated, which suits a market where imaging retains a confirmatory role even as blood testing captures first-line screening volume. Cognitive assessment tests remain established as a low-cost first step in the diagnostic pathway and are cheaper to administer than any biomarker test, but they cannot confirm the underlying amyloid or tau pathology that treatment eligibility decisions require. Biomarkers are expected to register the fastest revenue growth rate in the global Alzheimer's disease diagnostics market over the forecast period, driven by Fujirebio and Roche's FDA-cleared blood-based plasma assays, which is why Labcorp and Quest Diagnostics are both scaling nationwide blood biomarker testing infrastructure.

Screening type is expected to account for a significantly large revenue share in the global Alzheimer's disease diagnostics market during the forecast period

Based on type, the global Alzheimer's disease diagnostics market is segmented into diagnosis, screening, and triage. Diagnosis holds the largest revenue share, because confirmatory amyloid and tau pathology testing remains the necessary final step before any anti-amyloid treatment decision, which suits a market where confirmatory testing revenue is protected even as screening volume grows around it. Screening is expected to register the fastest revenue growth rate in the global Alzheimer's disease diagnostics market over the forecast period, driven by blood-based tests being cleared specifically for primary-care rule-out use, which is why C2N Diagnostics and Roche are both positioning their plasma assays as a population-level triage step ahead of specialist referral.

Based on biomarker, the global Alzheimer's disease diagnostics market is segmented into amyloid-beta biomarkers, tau and phospho-tau biomarkers, neurodegeneration biomarkers, and PET radiotracer diagnostics. Tau and phospho-tau biomarkers hold the largest revenue share, because p-tau217 and p-tau181 are the analytes underlying both FDA-cleared blood tests now on the market, which ties directly back to the regulatory clearance activity described in the market's primary demand driver. Neurodegeneration biomarkers such as NfL and GFAP are expected to register the fastest revenue growth rate in the global Alzheimer's disease diagnostics market over the forecast period, driven by their emerging use in monitoring disease progression alongside anti-amyloid treatment response, which is why Quanterix's Simoa ultra-sensitive platform is expanding its neurodegeneration biomarker menu.

Based on regional analysis, the Alzheimer's disease diagnostics market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of FDA-cleared blood biomarker tests and anti-amyloid therapy approvals creates a direct testing-to-treatment pathway, and because Fujirebio, Roche, Labcorp, and Quest Diagnostics all maintain their primary commercial and regulatory presence in the US market. The Alzheimer's Association reported that over 7 million Americans were living with Alzheimer's in 2025, anchoring a domestic patient population large enough to sustain multiple competing blood-based biomarker platforms simultaneously. The concentration of FDA clearance activity in the country also means new Alzheimer's biomarker assays are typically launched in the United States first, before expanding to other regulatory jurisdictions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. Roche's Elecsys pTau181 test received CE Mark certification in Europe around the same period as its FDA clearance, making it the first IVDR-certified blood test to help rule out Alzheimer's-related amyloid pathology in the region. The result is steady rather than rapid growth, shaped more by national health system reimbursement negotiation than by underlying patient demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and Japan represent the two largest national markets within the region, driven by rapidly aging populations and expanding blood-based testing deployment. China's National Medical Products Administration approved a five-biomarker Alzheimer's blood test in April 2024, and BGI Genomics and Roche Diagnostics deployed the test across several Chinese cities in January 2026, which leaves more room for growth than in the already imaging-saturated North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with private reference laboratory networks driving early blood-based biomarker test adoption among higher-income patients. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the radiopharmaceutical precursor materials and diagnostic reagents that Latin American imaging and laboratory networks depend on, an effect expected to run through 2026 and slow Alzheimer's diagnostics adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding private hospital network and the UAE's regional diagnostic laboratory hubs represent the primary investment centres for Alzheimer's diagnostics adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the specialist memory-clinic and laboratory infrastructure needed to support blood-based testing at scale.